TIBET AIM PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 81.7633 million yuan, an increase of 95.52%

TIBET AIM PHARM released its third-quarter report for 2025, with operating revenue of 489 million yuan in the first three quarters, a year-on-year decrease of 4.65%. The net profit attributable to shareholders of the listed company was 81.7633 million yuan, a year-on-year increase of 95.52%. The net profit after deducting non-recurring gains and losses was 39.9473 million yuan, a year-on-year increase of 144.50%. The basic earnings per share were 0.44 yuan

TIBET AIM PHARM: Received government subsidies of 19.3227 million yuan

On the evening of September 16th, TIBET AIM PHARM announced that the company recently received a government subsidy of 19.3227 million yuan, accounting for 42.07% of the audited net profit attributable to shareholders of the listed company for the fiscal year 2024

The chemical pharmaceutical sector fluctuated and weakened, with TIBET AIM PHARM hitting the limit down, followed by Lifeon Pharmaceutical, JLPC, huahaipharm, Foyou Pharma, and CHENGYIPHARMA

The actual controller of TIBET AIM PHARM has changed to Yao Jinbo

According to the Zhitong Finance APP, TIBET AIM PHARM announced that the company's former controlling shareholder and actual controller, Gao Fan, will transfer 43.86 million shares of the company (accounting for 23% of the total shares of the listed company) to Beijing Fuhai through an agreement, with the transfer date set for August 19, 2025. After this equity change is completed, Beijing Fuhai will hold 43.86 million shares of the company (accounting for 23% of the total shares of the listed company), and the company's controlling shareholder will change from Gao Fan to Beijing Fuhai, with the actual controller changing from Gao Fan to Yao Jinbo

TIBET AIM PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 37.5571 million yuan, a year-on-year decrease of 5.27%

TIBET AIM PHARM released its semi-annual report for 2025, with operating revenue of 311 million yuan, a year-on-year decrease of 11.52%; net profit attributable to the parent company was 37.5571 million yuan, a year-on-year decrease of 5.27%; net profit excluding non-recurring gains and losses was 25.0222 million yuan, a year-on-year increase of 102.33%; basic earnings per share were 0.2 yuan